Sequential, cycling maintenance therapy for post transplant multiple myeloma.

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• High-dose chemotherapy with autologous stem cell transplantation (ASCT) prolongs survival in multiple myeloma but is not curative.
• Maintenance therapy following ASCT is crucial for prolonging disease-free interval (DFI) and potentially overall survival (OS).

Purpose of the Study:

• To evaluate the safety and efficacy of a novel sequential, cycling maintenance regimen in patients with newly diagnosed multiple myeloma post-ASCT.
• To assess the impact of this maintenance strategy on event-free survival (EFS) and overall survival (OS).

Main Methods:

• A phase II pilot study enrolled 28 patients with multiple myeloma post-ASCT.
• A 12-month sequential cycling maintenance regimen included dexamethasone, melphalan/prednisone, cyclophosphamide/prednisone, and alpha-interferon, followed by a drug holiday.
• Toxicity and survival outcomes (EFS, OS) were monitored.

Main Results:

• The regimen was generally well-tolerated, with reversible grade III-IV toxicities observed in five patients (four with hyperglycemia, one with neutropenia).
• One toxic death occurred due to non-neutropenic pneumonia and sepsis.
• Median EFS from transplant was 36.9 months; median OS had not been reached at a median follow-up of 44 months.

Conclusions:

• A sequential, cycling maintenance regimen using various myeloma agents is feasible and generally well-tolerated post-ASCT.
• This maintenance approach demonstrates encouraging EFS and OS, supporting further investigation in multiple myeloma.
• Future studies could explore incorporating novel biological and targeted agents into sequential maintenance strategies.